What is ventricular heart disease, including its types, etiologies, clinical presentation, diagnostic evaluation, and management recommendations, as described in Harrison's Principles of Internal Medicine?

Ventricular Heart Disease: Comprehensive Overview

Definition and Classification

Ventricular heart disease encompasses disorders affecting the ventricles that impair their ability to fill with or eject blood, leading to mechanical or electrical dysfunction. 1 This includes both structural abnormalities and functional impairments that result in heart failure, arrhythmias, or sudden cardiac death. 2, 3

Primary Categories

Left Ventricular Disease:

• Systolic dysfunction with reduced ejection fraction (HFrEF), where coronary artery disease accounts for approximately two-thirds of cases 4, 5
• Diastolic dysfunction with preserved ejection fraction (HFpEF), affecting 20-40% of heart failure patients, predominantly elderly women with hypertension 5
• Cardiomyopathies including dilated, hypertrophic, restrictive, and infiltrative diseases 6

Right Ventricular Disease:

• Secondary to left heart disease, representing the most common form of pulmonary hypertension (65-80% of cases) 7
• Arrhythmogenic right ventricular cardiomyopathy (ARVC), with prevalence of 1:2,000 to 5,000 6
• Acute RV failure from pulmonary embolism, ARDS, or RV infarction 8

Etiologies

Left Ventricular Disease

• Ischemic heart disease: 40% of global heart failure cases and two-thirds of systolic dysfunction 4, 5
• Hypertension: Primary driver of diastolic dysfunction and HFpEF 5
• Valvular heart disease: Aortic stenosis, mitral regurgitation, mitral valve prolapse 2, 9
• Cardiomyopathies: Dilated (1:250-500 prevalence), hypertrophic (1:250-500), restrictive 6
• Toxins and medications: Alcohol, chemotherapy agents, cocaine, amphetamines 2, 9
• Myocarditis and inflammatory diseases 6

Right Ventricular Disease

• Left heart disease: Most common cause of RV dysfunction 7, 10
• Pulmonary hypertension: Both primary and secondary forms 7
• Coronary disease: RV infarction 8
• Congenital heart disease 3

Clinical Presentation

Symptoms of Left Ventricular Failure

Cardinal manifestations include dyspnea and fatigue limiting exercise tolerance, plus fluid retention causing pulmonary congestion and peripheral edema. 1, 5

• Dyspnea: Initially with exertion, progressing to rest in advanced disease 5
• Orthopnea and paroxysmal nocturnal dyspnea: Reflecting elevated left ventricular filling pressures 5
• Fatigue and reduced exercise capacity: Severely limiting functional status and quality of life 5
• Chest pain: May indicate underlying ischemia or pericardial involvement 2
• Palpitations, lightheadedness, syncope: Suggesting ventricular arrhythmias 2, 9

Symptoms of Right Ventricular Failure

• Jugular venous distention with elevated jugular venous pressure 10
• Peripheral edema: Ankle swelling progressing to generalized edema 10
• Congestive hepatomegaly and ascites in advanced cases 10
• Dyspnea and exercise intolerance from impaired cardiac output 8

NYHA Functional Classification

• Class I: Symptoms only with efforts limiting normal individuals 5
• Class II: Symptoms with ordinary effort 5
• Class III: Symptoms with less than ordinary effort 5
• Class IV: Symptoms at rest 5

Diagnostic Evaluation

History and Physical Examination

Critical historical elements to elicit:

• Symptom characteristics: Palpitations, lightheadedness, syncope, dyspnea at rest or exertion, orthopnea, paroxysmal nocturnal dyspnea, chest pain, edema 2, 9
• Precipitating factors: Exercise, emotional stress 2, 9
• Known cardiac disease: Coronary, valvular (mitral valve prolapse), congenital 2, 9
• Risk factors: Hypertension, diabetes, hyperlipidemia, smoking 2
• Medications: Antiarrhythmics, QT-prolonging drugs, stimulants including cocaine and amphetamines 2, 9
• Past medical history: Thyroid disease, kidney disease, electrolyte abnormalities, stroke, epilepsy (arrhythmic syncope misdiagnosed as epilepsy), alcohol or illicit drug use 2, 9
• Family history: Sudden cardiac death, sudden cardiac arrest, unexplained drowning in first-degree relatives; SIDS; cardiomyopathy; cardiac channelopathies (long QT, Brugada, short QT, CPVT); neuromuscular disease 2, 9

Physical examination findings:

• Vital signs: Heart rate irregularity, blood pressure, effective bradycardia from bigeminy/trigeminy with apical-radial pulse deficit 2, 9
• Jugular venous pressure elevation 2, 9, 10
• Cardiac auscultation: Murmurs (aortic stenosis, mitral regurgitation), midsystolic click (mitral valve prolapse), gallops, rales 2, 9
• Vascular examination: Carotid bruits, diminished peripheral pulses indicating atherosclerotic disease 2, 9
• Peripheral edema 2, 9, 10
• Sternotomy scars 9

Initial Diagnostic Testing

Transthoracic echocardiography is the diagnostic standard and must be obtained in all patients with known or suspected ventricular heart disease. 3, 11, 4, 12

Echocardiographic assessment includes:

• Left ventricular ejection fraction, chamber size, ventricular mass 4, 13
• Wall motion abnormalities suggesting ischemia or infarction 12
• Valvular abnormalities and severity 11, 4
• Diastolic filling patterns providing prognostic information 13
• Right ventricular size and function 11, 7
• Pulmonary systolic pressure estimation 11, 7
• Functional mitral regurgitation as marker of adverse prognosis 13

Laboratory evaluation:

• Complete blood count, urinalysis, fasting lipid profile 4
• Liver function tests, serum electrolytes, blood urea nitrogen, serum creatinine 4
• Fasting glucose, thyroid-stimulating hormone 4
• BNP or NT-proBNP when clinical uncertainty exists, with high negative predictive value for ruling out heart failure 4

Electrocardiogram:

• Identify arrhythmias, conduction abnormalities, bundle-branch block, ventricular hypertrophy 3
• Q waves indicating ischemic disease or infiltrative cardiomyopathy 3
• QT interval assessment for channelopathies and torsades de pointes risk 2, 3

Chest radiograph:

• Assess pulmonary congestion and lung pathology 11

Advanced Diagnostic Testing

Exercise testing is recommended in patients with:

• Intermediate or greater probability of coronary disease to provoke ischemic changes or ventricular arrhythmias 3
• Known or suspected exercise-induced ventricular arrhythmias including catecholaminergic VT 3
• Evaluation of response to medical or ablation therapy 3

Cardiac catheterization when:

• Noninvasive testing yields inconclusive data 11
• Discrepancy exists between noninvasive tests and clinical findings 11
• Direct intracardiac pressure measurements and cardiac output determination needed 11

Alternative imaging modalities:

• Cardiac MRI or CT when echocardiography is inadequate or additional tissue characterization needed 6, 4
• TEE for detailed valvular assessment or when transthoracic windows are poor 11
• PET imaging for viability assessment or specific infiltrative diseases 11

Risk stratification tools:

• T-wave alternans for improving diagnosis and risk stratification of life-threatening ventricular arrhythmias 3
• Signal-averaged ECG, heart rate variability, baroflex sensitivity, heart rate turbulence may be useful 3

Serial Monitoring

Repeat echocardiography is indicated when:

• Change in clinical status occurs 4
• Patient experiences or recovers from a clinical event 4
• Treatment that might significantly affect cardiac function has been administered 4
• Every 1-2 years if PVC burden is high to monitor for left ventricular dysfunction 12

Serial laboratory monitoring:

• Renal function and serum electrolytes to guide diuretic therapy and detect medication complications 4

Management Recommendations

Left Ventricular Systolic Dysfunction (HFrEF)

Guideline-directed medical therapy forms the foundation:

• ACE inhibitors or ARBs as first-line agents 5
• Beta-blockers to improve survival and reduce hospitalizations 5
• Diuretics for congestion management with careful monitoring 5
• Device therapy (ICD, CRT) based on LVEF and QRS duration per established guidelines 2

Left Ventricular Diastolic Dysfunction (HFpEF)

Blood pressure control is paramount, with aggressive management crucial. 5

• ACE inhibitors or ARBs as first-line agents to improve ventricular relaxation and promote regression of left ventricular hypertrophy 5
• Beta-blockers to control heart rate and increase diastolic filling time 5
• Diuretics used judiciously to reduce congestion and elevated filling pressures, with careful monitoring to avoid hypotension 5

Ventricular Arrhythmias

Management depends on presence of structural heart disease and symptom burden:

In structurally normal hearts:

• Asymptomatic PVCs carry excellent prognosis and do not require antiarrhythmic therapy 12
• Beta-blockers or non-dihydropyridine calcium channel blockers if symptoms develop 12
• Avoid Class IC antiarrhythmic agents without first excluding coronary artery disease and structural heart disease 12

In structural heart disease:

• Guideline-directed heart failure therapy and device implantation are critical 14
• Catheter ablation increasingly considered first-line alternative to medical therapy, particularly if PVC burden exceeds 15-20% or PVC-induced cardiomyopathy develops 12, 14
• Antiarrhythmic drugs when ablation not feasible, though limited by toxicity 14

Right Ventricular Failure

Identify and treat underlying cause as primary management strategy:

• Acute pulmonary embolism, ARDS, acute decompensation of chronic pulmonary hypertension, RV infarction, arrhythmia 8
• Judicious fluid management avoiding excessive preload 8
• Inotropes and vasopressors for hemodynamic support 8
• Mechanical ventilation with RV-protective strategy if required 8
• Assist devices in refractory cases 8

Critical Pitfalls to Avoid

Do not dismiss heart failure based solely on absence of peripheral edema or pulmonary rales, as these signs may be absent in early stages or well-treated patients. 4

Do not treat asymptomatic PVCs with antiarrhythmic drugs in patients without structural heart disease, as risks outweigh benefits. 12

Do not overlook family history of sudden cardiac death, cardiomyopathy, or channelopathies, as these significantly alter risk stratification and management. 2, 9

Do not ignore medications causing QT prolongation (www.crediblemeds.org) or inducing Brugada pattern (www.brugadadrugs.org). 2, 9

Do not underestimate effective bradycardia from bigeminy/trigeminy, which can result in inaccurate heart rate estimation and hemodynamic compromise. 2, 9

Always identify the underlying cause of heart failure, as specific etiologies require targeted treatments beyond standard heart failure management. 4